A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

LESSONS LEARNED. The combination of pexidartinib and binimetinib was safe and tolerable and demonstrated encouraging signs of efficacy in two patients with advanced gastrointestinal stromal tumor (GIST) refractory to tyrosine kinase inhibitors (TKIs). Molecular profiling of GISTs at diagnosis and up...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Rosenbaum, Evan, Kelly, Ciara, D'Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal, Keohan, Mary L., Movva, Sujana, Condy, Mercedes, Adamson, Travis, Mcfadyen, Chloe R., Antonescu, Christina R., Hwang, Sinchun, Singer, Sam, Qin, Li‐Xuan, Tap, William D., Chi, Ping
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2019
Sujets:
Clinical Trial Results
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795162/
https://ncbi.nlm.nih.gov/pubmed/31213500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0418
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires